 |
|
|
||||||||||||||
 |
|
|
One simple test could change the future
The test is intended for use by physicians as an aid in management of patients considered to be at risk for Type 2 diabetes.
The PreDx™ Diabetes Risk Test is performed using a routine fasting blood sample. It quantifies a panel of biomarkers, resulting in a single score: the PreDx™ Diabetes Risk Score. The biomarkers used in the PreDx Diabetes Risk Test were selected by testing baseline samples from individuals 30 to 60 years of age who developed diabetes within 5 years and a random selection of controls from the same population.1-3 Using mathematical modeling, the PreDx Diabetes Risk Test combines multiple biomarkers into a single diabetes risk factor between 1 (least risk) and 10 (highest risk).2
NOTE: The PreDx Diabetes Risk Test is an adjunctive test to complement, not replace, other diagnostic and clinical procedures.
The PreDx™ Diabetes Risk Score may be used as a motivational tool in helping to increase patient compliance for those at high risk.
*Performed exclusively by the Tethys Clinical Laboratory
1. Population description: Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. European Journal of Cardiovascular Prevention and Rehabilitation 2003;10:377-386.
2. Data on file, Tethys Clinical Laboratory, Tethys Bioscience, Inc., 2008
3. Kolberg J, Gerwien R, Moler E, Rowe M, Urdea M, McKenna M, Hansen T, Pedersen O, Jørgensen T. Training and validation of a multimarker algorithm for the prediction of Type 2 diabetes from a 5 yr prospective study of 6,784 Danish people (Inter99). American Diabetes Association 68th Scientific Sessions, 2008.
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)